Table of Contents

    Topic review

    TRPC Channels in Cardiac Plasticity

    Subjects: Cell Biology
    View times: 5
    Submitted by: Takuro Numaga-Tomita


    The heart flexibly changes its structure in response to changing environments and oxygen/nutrition demands of the body. Increased and decreased mechanical loading induces hypertrophy and atrophy of cardiomyocytes, respectively. In physiological conditions, these structural changes of the heart are reversible. However, chronic stresses such as hypertension or cancer cachexia cause irreversible remodeling of the heart, leading to heart failure. Accumulating evidence indicates that calcium dyshomeostasis and aberrant reactive oxygen species production cause pathological heart remodeling. Canonical transient receptor potential (TRPC) is a nonselective cation channel subfamily whose multimodal activation or modulation of channel activity play important roles in a plethora of cellular physiology.

    1. Introduction

    The heart is a pump, delivering oxygen and nutrients to all tissues in the body through blood vessels. During development, heart size and contractile force gradually increase, which is accompanied by structural changes, e.g., hypertrophy, T-tubule formation, and arrangement of sarcomeres [1]. However, the completely developed adult heart changes its structure in response to the hemodynamic load caused by body demands. Flexible changes of heart structure are caused by individual cardiomyocytes and non-cardiomyocyte cells in the heart. Structural changes of cardiomyocytes are directly linked to their contractile force [2]. Therefore, increased oxygen or nutrition demands by the body increase muscle mass of the heart, which is provided by cardiac hypertrophy. In contrast, reduced hemodynamic load to the heart induces a reduction of cardiac muscle mass, which is caused by cardiomyocyte atrophy. In addition, nonmyocyte cells such as cardiac fibroblasts also play important roles to regulate structural integrity and electrical conduction in the heart by regulating extracellular matrix proteins [3]. Although flexible changes of the heart structure are an inherently adaptive feature, many cardiac diseases are brought about by maladaptive cardiac responses to chronic stresses. Therefore, understanding of the underlying mechanism of cardiac plasticity is important for both the prevention of and protection from cardiovascular diseases.

    2. Canonical Transient Receptor Potential (TRPC) Channels

    The trp gene was first discovered in a phototransduction mutant of Drosophila [4]. A spontaneous mutation in trp resulted in a transient receptor potential in response to continuous light. There are 28 mammalian TRP homologues, which can be further divided into six subfamilies based on genetic and functional similarities: TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin), and TRPA (ankyrin). TRP channels have common structural features, including six transmembrane domains, a pore domain between the fifth and sixth transmembrane domains, and a preserved 25-amino-acid sequence termed the ‘TRP domain’. TRPC family proteins, comprising seven mammalian homologues (TRPC1–TRPC7), are the most evolutionally preserved TRP channels with regard to the original form identified in Drosophila. Therefore, it was believed and later demonstrated that they function as receptor-activated calcium channels [5]. Among them, TRPC4 and TRPC5 have about 65% amino acid homology, while TRPC3, TRPC6, and TRPC7 have about 75% homology [6]. TRPC1 was originally reported as a candidate subunit of store-operated Ca2+ channels [7][8][9][10]. The functional importance of TRPC1 channels is manifested by the promotion of functional coupling between endoplasmic reticulum and the plasma membrane during receptor-induced Ca2+ signaling [11]. In addition, it has been shown that mechanical stretch activates TRPC1 in mammalian cells [12]. Thus, TRPC proteins have two important roles: one as a functional channel activated by mechanical stretch or endoplasmic reticulum store depletion and the other as a platform to organize receptor-activated Ca2+ channels and intracellular signaling molecules for efficient signal transduction [13].
    TRPC channels are widely recognized to be activated downstream of phospholipase C (PLC)-coupled receptors such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases [13]. As a result of their universal activation mechanism in many cell types, TRPC channels play important roles in basic cellular responses including proliferation, differentiation, and death in response to various environmental stimuli. Recent findings indicate that in addition to PLC-mediated activation, TRPC channels are multimodally activated by environmental stimuli such as mechanical stretch, hypoxia, and oxidative stress [14][15][16][17][18][19]. In particular, TRPC1 and TRPC6 are suggested to be activated by mechanical stimuli [12][20]. Later studies suggested that mechanical activation of TRPC1 and TRPC6 is mediated by phospholipase-dependent mediators [21][22][23][24]. Physiological or pathophysiological conditions expose the heart to changes in mechanical loading and oxygen supply, as well as oxidative stress, especially in the pathological heart. Therefore, TRPC channels play important roles in transducing these environmental stimuli into Ca2+ and/or chemical signals within cardiomyocytes.
    All TRPC channels are expressed in cardiomyocytes, except TRPC2. The expression of some of these channels is not high in normal conditions but is increased in the failing heart [25]. According to studies using heterologous expression systems, the TRPC family can be further subdivided into two groups: TRPC1/C4/C5 and TRPC3/C6/C7. Apart from several observations, TRPC channels form functional channels by forming homo- or heterotetramers within these groups. So far, heterologous expression systems have demonstrated that the difference between these two groups involves activation by the PLC product of diacylglycerol (DAG) [26]. TRPC3/C6/C7 is activated directly by DAG, whereas TRPC1/C4/C5 is not [27]. However, Storch et al. recently revealed that DAG activates TRPC4/TRPC5 [28]. Structural analysis with cryogenic electron microscopy revealed the structural conservation of TRPC family channels [29][30][31][32]. This is further supported by the fact that a glycine residue in the selective filter of TRPC3 is both critical to the recognition of lipid mediators and conserved among TRPC channels [33]. Although the actual mechanism of TRPC channel downstream surface receptor activation is still not completely understood [34], its importance in cardiac plasticity has been extensively documented in the model of neurohumoral-factor-induced cardiac remodeling. The original concept of TRPC channels in cardiac remodeling is quite simple. First, major pro-hypertrophic factors such as angiotensin II (AngII) and endothelin-1 activate their receptors, which couple to PLC and downstream TRPC channels. Second, TRPC channels mediate Ca2+ influx, which activates major hypertrophic signaling of calcineurin (CaN)/nuclear factor of activated T cells (NFAT). However, recent findings indicate that the involvement of TRPC channels is more complex and chaotic. At present, it is not easy to understand and conceptualize the importance of TRPC channels in cardiac plasticity. Therefore, we herein review recent findings about TRPC channels in cardiac remodeling and raise models and questions that need to be addressed in the near future.

    3. Cardiac Hypertrophy

    The heart changes its size and contractility in response to increased or decreased hemodynamic load caused by body demand for oxygen and nutrition supplies [1][2]. The best-known adaptive change of the heart is hypertrophy. However, continued increase of the pressure for hypertrophy leads to maladaptive changes of the heart, ultimately resulting in heart failure. Numerous signaling pathways have been implicated in cardiac hypertrophy [35]. Cardiac hypertrophy is an inherently adaptive response. Athletes or pregnant women experience cardiac hypertrophy, but most of this is completely reversible. The heart size returns to a normal level by attenuation of physical activity or after delivery. Several studies have demonstrated the difference between physiological and pathological cardiac hypertrophy [35]. Physiological and pathological hypertrophy have distinct features at structural, metabolic, and molecular levels. Physiological hypertrophy is accompanied by angiogenesis. In contrast, pathological hypertrophy is accompanied by interstitial fibrosis and reduced capillary densities, which result in myocardial ischemia and lead to heart failure [36][37]. During cardiac hypertrophy, the heart remodels its metabolic pathways to increase ATP production. In physiological hypertrophy, fatty acid and glucose oxidation are increased, in contrast to decreases observed during pathological hypertrophy [38]. In response, the glycolytic pathway is upregulated in pathological hypertrophy, likely to compensate for reduced mitochondrial ATP production. Interestingly, the fetal heart depends on the glycolytic pathway because of the poor availability of fatty acids [35]. Moreover, it has been well recognized that the molecular features of pathological hypertrophy include increased fetal gene expression [39]. Thus, pathological hypertrophy occurs concurrently with a regression to a fetal heart phenotype with regard to metabolic and genetic aspects.
    The best-known signaling pathway regulating physiological hypertrophy is the insulin-like growth factor 1-PI3K(p110α)-Akt pathway. Insulin-like growth factor 1 is important for postnatal development and in the exercised adult heart [40]. Two major pathways have been implicated in pathological cardiac hypertrophy; one is neurohumoral-factor-dependent while the other is biomechanical-stress-dependent [1]. The neurohumoral-factor-dependent pathway is mediated by Gq-type GPCRs, such as AngII receptor type 1 (AT-1) and endothelin receptor. Many signaling pathways participate in pathological hypertrophy, such as small G proteins, mitogen-activated protein kinases, histone deacetylases, and calcium signaling, which are integrated under transcriptional control by several transcription factors. [35][41]. Altered Ca2+ signaling, one trigger for cardiac hypertrophy, is likely attributable to changes of PLC and phosphatidylinositol-turnover-dependent increases in intracellular Ca2+ [42][35][43]. Although how cardiomyocytes sense and transduce biomechanical signals into hypertrophy is still largely unknown, some reports have demonstrated increased autocrine and paracrine secretion of pro-hypertrophic neurohumoral factors and growth factors in mechanically stressed cardiomyocytes [44]. Alternatively, ligand-independent activation of AT-1 receptors by mechanical stretch might mediate abnormal Ca2+ increases [45]. Several Ca2+ signaling molecules have been identified as critical regulators of cardiac hypertrophy. Most notably, activity of the Ca2+-dependent transcriptional pathway of CaN/NFAT is important for pathological cardiac hypertrophy [43]. Therefore, it is very likely that Ca2+-permeable channels play important roles in abnormal Ca2+ signaling in pathological cardiac hypertrophy. As a candidate molecular entity for those Ca2+ channels, TRPC channels have been intensively studied.
    Both mRNA and protein expression levels of TRPC1 are increased in the hearts of cardiac hypertrophy model rats [46][47][48]. In addition, several experiments demonstrated that TRPC1 plays a critical role in neurohumoral-factor-induced cardiac hypertrophy in vitro [48][49]. TRPC1-knockout mice showed no cardiac hypertrophy after transverse aortic constriction [23]. In addition to these animal model studies, patients with cardiac hypertrophy or heart failure showed increased expression of TRPC1 mRNA [50]. In addition, the involvement of TRPC1 in cardiac hypertrophy was demonstrated in human embryonic stem cell derived cardiomyocytes [50]. As hypertrophied cardiomyocytes have larger SOCE, upregulation of TRPC1 contributes to increased responses that subsequently activate the CaN/NFAT pathway, leading to pathological hypertrophy [46][47]. In addition to this well-known pathway, RNA sequencing of human cardiomyocytes indicates that downstream signaling of TRPC1 involves the NF-κB pathway [50].
    Suppression of TRPC4 activity by expression of a dominant-negative mutant of TRPC4 suppressed transverse aortic constriction induced cardiac hypertrophy [51]. Furthermore, the heart expresses several TRPC4 splice variants from α to γ [52][53]. Among these variants, only TRPC4a can interact with PLCβ1b and is expressed on the sarcolemma. Overexpression of TRPC4a in cardiomyocytes induces cardiomyocyte hypertrophy [52]. However, chronic treatment with pro-hypertrophic AngII does not further increase the size of cardiomyocytes. In addition, TRPC4b overexpression has nothing to do with resting or AngII-induced cardiac hypertrophy. In both TRPC4a- and TRPC4b-overexpressing cardiomyocytes, basal activity of the CaN/NFAT pathway is increased [54]. Consistent with these findings, the most important role of TRPC1/C4 seems to be the pathway for background Ca2+ entry in cardiomyocytes to fine-tune systolic and diastolic intracellular Ca2+ concentration [55]. These results suggest that TRPC4 channel isoforms have different functions in cardiomyocytes and affect downstream targets of universal CaN/NFAT signaling in cardiac hypertrophy (Figure 1).
    Figure 1. Schematic representation of canonical transient receptor potential (TRPC) channels in cardiac plasticity. Neurohumoral-factor-induced cardiac hypertrophy is mediated by the CaN/NFAT pathway. TRPC3/C6 channels contribute to Ca2+ increase downstream of GPCR activation. TRPC1/C4 channels function to regulate background Ca2+ entry and the basal level of CaN/NFAT activation in cardiomyocytes. Homomeric TRPC3 channels are upregulated by mechanical stresses. TRPC3 prevents Nox2 from undergoing proteasomal degradation, leading to increased Nox2 protein abundance. TRPC3 is also important for enzymatic activation of Nox2. TRPC3–Nox2 coupling mediates chemical (DOX) and nutritional stress-induced cardiac atrophy. Chemical/nutritional stresses evoke ATP release from cardiomyocytes, which activates Gq-coupled P2Y2 receptors.

    4. Cardiac Atrophy

    Cardiac muscle mass is decreased in response to a reduction of hemodynamic load, which is known to be caused by microgravity, long-term bed rest, or cancer cachexia. Cardiac atrophy is mediated by increased protein breakdown by the ubiquitin–proteasome system, Ca2+-dependent calpain system, lysosomal system, and autophagy [56]. Hemodynamic unloading by heart transplantation has revealed that unloading stresses increase the expression of calpain proteases [57] and E3 ubiquitin ligases MuRF1 and atrogin-1 [58]. Interestingly, Taegtmeyer’s group observed similar induction of a fetal gene program in atrophied hearts as demonstrated in hypertrophied hearts [39][56]. Activation of the fetal gene program seems to be an adaptive response to metabolic changes of the heart. Therefore, atrophic responses of the heart are not a passive reduction of muscle mass but an active remodeling of heart structure and function occurring in response to a change of hemodynamic load. Compared with hypertrophic responses, underlying mechanisms of cardiac atrophy remain largely elusive. Ca2+ signaling likely plays important roles in cardiac atrophy, as the calpain system requires increases of intracellular Ca2+ [59], and some reports have demonstrated Ca2+ dyshomeostasis in unloaded cardiomyocytes [60][61]. The molecular mechanism underlying cardiac atrophy is presumed based on observations of skeletal muscle atrophy. In skeletal muscle, mechanical unloading causes mitochondrial dysfunction and reactive oxygen species (ROS) production.
    In contrast to cardiac hypertrophy, the molecular mechanism of cardiac atrophy remains largely unknown. Doxorubicin (DOX) is a highly effective anticancer drug prescribed for a wide range of cancers. However, the dose-dependent cardiotoxic effects of DOX limits its long-term use. Specifically, the cardiotoxic effects of DOX include arrhythmias induced by its acute effect, the development of left ventricular systolic dysfunction (which leads to dilated cardiomyopathy), and congestive heart failure induced by its chronic effect [62][63]. It was demonstrated that DOX initially induces cardiac shrinkage followed by the induction of myocardial apoptosis and interstitial fibrosis at later stages of left ventricular dilated cardiomyopathy [64][65]. In Nox2–/– mice, DOX-induced structural remodeling was completely attenuated [66]. DOX treatment has been shown to increase Nox2 expression in the heart [66][67][68]. Strikingly, the reduction of Nox2 expression by treatment with paeoniflorin suppressed DOX-induced cardiomyocyte apoptosis [67]. In our mouse model, DOX treatment induced cardiac atrophy from 2 weeks after treatment. DOX treatment increased Nox2 protein abundance, which was significantly suppressed by the absence of TRPC3. TRPC3-knockout mouse hearts maintained both whole-heart and cross-sectional areas of cardiomyocytes [68]. Therefore, similar to mechanical overloading, TRPC3 can couple with Nox2 in DOX-induced cardiac atrophy. We recently revealed that nutritional deficiency caused by glucose and amino acid starvation and hypoxia induces cardiomyocyte atrophy [69]. Nutritional stresses evoke intracellular ATP release to the extracellular space, as has been demonstrated in cardiomyocytes and other cells [70][71][72]. Extracellular ATP is the actual signal inducing atrophic responses in cardiomyocytes. As mentioned above, it is known that extracellular ATP does not induce cardiac hypoxia, even with a significant increase of the CaN/NFAT pathway. Atrophic responses of cardiomyocytes could be observed with stimulation of around 1 mM extracellular ATP. A submaximal concentration of ATP (e.g., 100 μM) does not induce atrophic responses. However, the dose responses of ATP to cardiomyocyte atrophy correlated well with intracellular ROS production. Indeed, high ATP stimulation does not increase TRPC3 or Nox2 protein abundances but enhances the interaction between them. Atrophic responses caused by both nutritional stresses and high extracellular ATP are sensitive to the specific P2Y2 receptor antagonist, indicating that the P2Y2 receptor is upstream of TRPC3–Nox2 coupling. Interestingly, DOX-induced atrophic responses were also suppressed by a P2Y2 receptor antagonist. These results suggest the critical involvement of intracellular ATP release and subsequent TRPC3 activation in stress-sensing and transduction of cardiomyocytes (Figure 1).

    The entry is from 10.3390/cells9020454


    1. Hill, J.A.; Olson, E.N. Cardiac plasticity. New Engl. J. Med. 2008, 358, 1370–1380.
    2. Mihl, C.; Dassen, W.R.; Kuipers, H. Cardiac remodelling: Concentric versus eccentric hypertrophy in strength and endurance athletes. Neth. Heart J. 2008, 16, 129–133.
    3. Bildyug, N. Extracellular Matrix in Regulation of Contractile System in Cardiomyocytes. Int. J. Mol. Sci. 2019, 20, 5054.
    4. Montell, C.; Rubin, G.M. Molecular characterization of the Drosophila trp locus: A putative integral membrane protein required for phototransduction. Neuron 1989, 2, 1313–1323.
    5. Ramsey, I.S.; Delling, M.; Clapham, D.E. An introduction to TRP channels. Annu. Rev. Physiol. 2006, 68, 619–647.
    6. Vazquez, G.; Wedel, B.J.; Aziz, O.; Trebak, M.; Putney, J.W., Jr. The mammalian TRPC cation channels. BBA 2004, 1742, 21–36.
    7. Wes, P.D.; Chevesich, J.; Jeromin, A.; Rosenberg, C.; Stetten, G.; Montell, C. TRPC1, a human homolog of a Drosophila store-operated channel. Proc. Natl. Acad. Sci. USA 1995, 92, 9652–9656.
    8. Zitt, C.; Zobel, A.; Obukhov, A.G.; Harteneck, C.; Kalkbrenner, F.; Luckhoff, A.; Schultz, G. Cloning and functional expression of a human Ca2+-permeable cation channel activated by calcium store depletion. Neuron 1996, 16, 1189–1196.
    9. Zhu, X.; Jiang, M.; Peyton, M.; Boulay, G.; Hurst, R.; Stefani, E.; Birnbaumer, L. trp, a novel mammalian gene family essential for agonist-activated capacitative Ca2+ entry. Cell 1996, 85, 661–671.
    10. Liu, X.; Cheng, K.T.; Bandyopadhyay, B.C.; Pani, B.; Dietrich, A.; Paria, B.C.; Swaim, W.D.; Beech, D.; Yildrim, E.; Singh, B.B.; et al. Attenuation of store-operated Ca2+ current impairs salivary gland fluid secretion in TRPC1(-/-) mice. Proc. Natl. Acad. Sci. USA 2007, 104, 17542–17547.
    11. Mori, Y.; Wakamori, M.; Miyakawa, T.; Hermosura, M.; Hara, Y.; Nishida, M.; Hirose, K.; Mizushima, A.; Kurosaki, M.; Mori, E.; et al. Transient receptor potential 1 regulates capacitative Ca(2+) entry and Ca(2+) release from endoplasmic reticulum in B lymphocytes. J. Exp. Med. 2002, 195, 673–681.
    12. Maroto, R.; Raso, A.; Wood, T.G.; Kurosky, A.; Martinac, B.; Hamill, O.P. TRPC1 forms the stretch-activated cation channel in vertebrate cells. Nat. Cell Biol. 2005, 7, 179–185.
    13. Nishida, M.; Hara, Y.; Yoshida, T.; Inoue, R.; Mori, Y. TRP channels: Molecular diversity and physiological function. Microcirculation 2006, 13, 535–550.
    14. Cioffi, D.L. Redox regulation of endothelial canonical transient receptor potential channels. Antioxid. Redox Signal. 2011, 15, 1567–1582.
    15. Yamaguchi, Y.; Iribe, G.; Nishida, M.; Naruse, K. Role of TRPC3 and TRPC6 channels in the myocardial response to stretch: Linking physiology and pathophysiology. Prog. Biophys. Mol. Biol. 2017, 130, 264–272.
    16. Veit, F.; Pak, O.; Brandes, R.P.; Weissmann, N. Hypoxia-dependent reactive oxygen species signaling in the pulmonary circulation: Focus on ion channels. Antioxid. Redox Signal. 2015, 22, 537–552.
    17. Kozai, D.; Ogawa, N.; Mori, Y. Redox regulation of transient receptor potential channels. Antioxid. Redox Signal. 2014, 21, 971–986.
    18. Ding, Y.; Winters, A.; Ding, M.; Graham, S.; Akopova, I.; Muallem, S.; Wang, Y.; Hong, J.H.; Gryczynski, Z.; Yang, S.H.; et al. Reactive oxygen species-mediated TRPC6 protein activation in vascular myocytes, a mechanism for vasoconstrictor-regulated vascular tone. J. Biol. Chem. 2011, 286, 31799–31809.
    19. Poteser, M.; Graziani, A.; Rosker, C.; Eder, P.; Derler, I.; Kahr, H.; Zhu, M.X.; Romanin, C.; Groschner, K. TRPC3 and TRPC4 associate to form a redox-sensitive cation channel. Evidence for expression of native TRPC3-TRPC4 heteromeric channels in endothelial cells. J. Biol. Chem. 2006, 281, 13588–13595.
    20. Spassova, M.A.; Hewavitharana, T.; Xu, W.; Soboloff, J.; Gill, D.L. A common mechanism underlies stretch activation and receptor activation of TRPC6 channels. Proc. Natl. Acad. Sci. USA 2006, 103, 16586–16591.
    21. Gottlieb, P.; Folgering, J.; Maroto, R.; Raso, A.; Wood, T.G.; Kurosky, A.; Bowman, C.; Bichet, D.; Patel, A.; Sachs, F.; et al. Revisiting TRPC1 and TRPC6 mechanosensitivity. Pflug. Archiv.: Eur. J. Physiol. 2008, 455, 1097–1103.
    22. Mederos y Schnitzler, M.; Storch, U.; Meibers, S.; Nurwakagari, P.; Breit, A.; Essin, K.; Gollasch, M.; Gudermann, T. Gq-coupled receptors as mechanosensors mediating myogenic vasoconstriction. EMBO J. 2008, 27, 3092–3103.
    23. Seth, M.; Zhang, Z.S.; Mao, L.; Graham, V.; Burch, J.; Stiber, J.; Tsiokas, L.; Winn, M.; Abramowitz, J.; Rockman, H.A.; et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ. Res. 2009, 105, 1023–1030.
    24. Inoue, R.; Jensen, L.J.; Jian, Z.; Shi, J.; Hai, L.; Lurie, A.I.; Henriksen, F.H.; Salomonsson, M.; Morita, H.; Kawarabayashi, Y.; et al. Synergistic activation of vascular TRPC6 channel by receptor and mechanical stimulation via phospholipase C/diacylglycerol and phospholipase A2/omega-hydroxylase/20-HETE pathways. Circ. Res. 2009, 104, 1399–1409.
    25. Numaga-Tomita, T.; Oda, S.; Shimauchi, T.; Nishimura, A.; Mangmool, S.; Nishida, M. TRPC3 Channels in Cardiac Fibrosis. Front. Cardiovasc. Med. 2017, 4, 56.
    26. Trebak, M.; Vazquez, G.; Bird, G.S.; Putney, J.W., Jr. The TRPC3/6/7 subfamily of cation channels. Cell Calcium 2003, 33, 451–461.
    27. Hofmann, T.; Obukhov, A.G.; Schaefer, M.; Harteneck, C.; Gudermann, T.; Schultz, G. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 1999, 397, 259–263.
    28. Storch, U.; Forst, A.L.; Pardatscher, F.; Erdogmus, S.; Philipp, M.; Gregoritza, M.; Mederos, Y.S.M.; Gudermann, T. Dynamic NHERF interaction with TRPC4/5 proteins is required for channel gating by diacylglycerol. Proc. Natl. Acad. Sci. USA 2017, 114, E37–E46.
    29. Vinayagam, D.; Mager, T.; Apelbaum, A.; Bothe, A.; Merino, F.; Hofnagel, O.; Gatsogiannis, C.; Raunser, S. Electron cryo-microscopy structure of the canonical TRPC4 ion channel. eLife 2018, 7.
    30. Tang, Q.; Guo, W.; Zheng, L.; Wu, J.X.; Liu, M.; Zhou, X.; Zhang, X.; Chen, L. Structure of the receptor-activated human TRPC6 and TRPC3 ion channels. Cell Res. 2018, 28, 746–755.
    31. Fan, C.; Choi, W.; Sun, W.; Du, J.; Lu, W. Structure of the human lipid-gated cation channel TRPC3. eLife 2018, 7.
    32. Duan, J.; Li, J.; Zeng, B.; Chen, G.L.; Peng, X.; Zhang, Y.; Wang, J.; Clapham, D.E.; Li, Z.; Zhang, J. Structure of the mouse TRPC4 ion channel. Nat. Commun. 2018, 9, 3102.
    33. Lichtenegger, M.; Tiapko, O.; Svobodova, B.; Stockner, T.; Glasnov, T.N.; Schreibmayer, W.; Platzer, D.; de la Cruz, G.G.; Krenn, S.; Schober, R.; et al. An optically controlled probe identifies lipid-gating fenestrations within the TRPC3 channel. Nat. Chem. Biol. 2018, 14, 396–404.
    34. Mederos, Y.S.M.; Gudermann, T.; Storch, U. Emerging Roles of Diacylglycerol-Sensitive TRPC4/5 Channels. Cells 2018, 7, 218.
    35. Bernardo, B.C.; Weeks, K.L.; Pretorius, L.; McMullen, J.R. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol. Ther. 2010, 128, 191–227.
    36. Hudlicka, O.; Brown, M.; Egginton, S. Angiogenesis in skeletal and cardiac muscle. Physiol. Rev. 1992, 72, 369–417.
    37. Shiojima, I.; Sato, K.; Izumiya, Y.; Schiekofer, S.; Ito, M.; Liao, R.; Colucci, W.S.; Walsh, K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Investig. 2005, 115, 2108–2118.
    38. Abel, E.D.; Doenst, T. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc. Res. 2011, 90, 234–242.
    39. Taegtmeyer, H.; Sen, S.; Vela, D. Return to the fetal gene program: A suggested metabolic link to gene expression in the heart. Ann. N. Y. Acad. Sci. 2010, 1188, 191–198.
    40. Troncoso, R.; Ibarra, C.; Vicencio, J.M.; Jaimovich, E.; Lavandero, S. New insights into IGF-1 signaling in the heart. Trends Endocrinol. Metab.: TEM 2014, 25, 128–137.
    41. Dirkx, E.; da Costa Martins, P.A.; De Windt, L.J. Regulation of fetal gene expression in heart failure. BBA 2013, 1832, 2414–2424.
    42. Eder, P. Cardiac Remodeling and Disease: SOCE and TRPC Signaling in Cardiac Pathology. Adv. Exp. Med. Biol. 2017, 993, 505–521.
    43. Houser, S.R.; Molkentin, J.D. Does contractile Ca2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes? Sci. Signal. 2008, 1, pe31.
    44. Sadoshima, J.; Izumo, S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 1997, 59, 551–571.
    45. Zou, Y.; Akazawa, H.; Qin, Y.; Sano, M.; Takano, H.; Minamino, T.; Makita, N.; Iwanaga, K.; Zhu, W.; Kudoh, S.; et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol. 2004, 6, 499–506.
    46. Sabourin, J.; Boet, A.; Rucker-Martin, C.; Lambert, M.; Gomez, A.M.; Benitah, J.P.; Perros, F.; Humbert, M.; Antigny, F. Ca(2+) handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy. J. Mol. Cell. Cardiol. 2018, 118, 208–224.
    47. Ohba, T.; Watanabe, H.; Murakami, M.; Takahashi, Y.; Iino, K.; Kuromitsu, S.; Mori, Y.; Ono, K.; Iijima, T.; Ito, H. Upregulation of TRPC1 in the development of cardiac hypertrophy. J. Mol. Cell. Cardiol. 2007, 42, 498–507.
    48. Chen, M.S.; Xiao, J.H.; Wang, Y.; Xu, B.M.; Gao, L.; Wang, J.L. Upregulation of TRPC1 contributes to contractile function in isoproterenol-induced hypertrophic myocardium of rat. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2013, 32, 951–959.
    49. Kiso, H.; Ohba, T.; Iino, K.; Sato, K.; Terata, Y.; Murakami, M.; Ono, K.; Watanabe, H.; Ito, H. Sildenafil prevents the up-regulation of transient receptor potential canonical channels in the development of cardiomyocyte hypertrophy. Biochem. Biophys. Res. Commun. 2013, 436, 514–518.
    50. Tang, L.; Yao, F.; Wang, H.; Wang, X.; Shen, J.; Dai, B.; Wu, H.; Zhou, D.; Guo, F.; Wang, J.; et al. Inhibition of TRPC1 prevents cardiac hypertrophy via NF-kappaB signaling pathway in human pluripotent stem cell-derived cardiomyocytes. J. Mol. Cell. Cardiol. 2019, 126, 143–154.
    51. Wu, X.; Eder, P.; Chang, B.; Molkentin, J.D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 2010, 107, 7000–7005.
    52. Cooley, N.; Grubb, D.R.; Luo, J.; Woodcock, E.A. The phosphatidylinositol(4,5)bisphosphate-binding sequence of transient receptor potential channel canonical 4alpha is critical for its contribution to cardiomyocyte hypertrophy. Mol. Pharmacol. 2014, 86, 399–405.
    53. Satoh, E.; Ono, K.; Xu, F.; Iijima, T. Cloning and functional expression of a novel splice variant of rat TRPC4. Circ. J. Off. J. Jpn. Circ. Soc. 2002, 66, 954–958.
    54. Kirschmer, N.; Bandleon, S.; von Ehrlich-Treuenstatt, V.; Hartmann, S.; Schaaf, A.; Lamprecht, A.K.; Miranda-Laferte, E.; Langsenlehner, T.; Ritter, O.; Eder, P. TRPC4alpha and TRPC4beta Similarly Affect Neonatal Cardiomyocyte Survival during Chronic GPCR Stimulation. PLoS ONE 2016, 11, e0168446.
    55. Camacho Londono, J.E.; Tian, Q.; Hammer, K.; Schroder, L.; Camacho Londono, J.; Reil, J.C.; He, T.; Oberhofer, M.; Mannebach, S.; Mathar, I.; et al. A background Ca2+ entry pathway mediated by TRPC1/TRPC4 is critical for development of pathological cardiac remodelling. Eur. Heart J. 2015, 36, 2257–2266.
    56. Baskin, K.K.; Taegtmeyer, H. Taking pressure off the heart: The ins and outs of atrophic remodelling. Cardiovasc. Res. 2011, 90, 243–250.
    57. Razeghi, P.; Volpini, K.C.; Wang, M.E.; Youker, K.A.; Stepkowski, S.; Taegtmeyer, H. Mechanical unloading of the heart activates the calpain system. J. Mol. Cell. Cardiol. 2007, 42, 449–452.
    58. Baskin, K.K.; Rodriguez, M.R.; Kansara, S.; Chen, W.; Carranza, S.; Frazier, O.H.; Glass, D.J.; Taegtmeyer, H. MAFbx/Atrogin-1 is required for atrophic remodeling of the unloaded heart. J. Mol. Cell. Cardiol. 2014, 72, 168–176.
    59. Letavernier, E.; Zafrani, L.; Perez, J.; Letavernier, B.; Haymann, J.P.; Baud, L. The role of calpains in myocardial remodelling and heart failure. Cardiovasc. Res. 2012, 96, 38–45.
    60. Ritter, M.; Su, Z.; Xu, S.; Shelby, J.; Barry, W.H. Cardiac unloading alters contractility and calcium homeostasis in ventricular myocytes. J. Mol. Cell. Cardiol. 2000, 32, 577–584.
    61. Korecky, B.; Ganguly, P.K.; Elimban, V.; Dhalla, N.S. Muscle mechanics and Ca2+ transport in atrophic heart transplants in rat. Am. J. Physiol. 1986, 251, H941–H948.
    62. Burridge, P.W.; Li, Y.F.; Matsa, E.; Wu, H.; Ong, S.G.; Sharma, A.; Holmstrom, A.; Chang, A.C.; Coronado, M.J.; Ebert, A.D.; et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 2016, 22, 547–556.
    63. Felker, G.M.; Thompson, R.E.; Hare, J.M.; Hruban, R.H.; Clemetson, D.E.; Howard, D.L.; Baughman, K.L.; Kasper, E.K. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. New Engl. J. Med. 2000, 342, 1077–1084.
    64. Cove-Smith, L.; Woodhouse, N.; Hargreaves, A.; Kirk, J.; Smith, S.; Price, S.A.; Galvin, M.; Betts, C.J.; Brocklehurst, S.; Backen, A.; et al. An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Toxicol. Sci.: An Off. J. Soc. Toxicol. 2014, 140, 3–15.
    65. Zhu, W.; Soonpaa, M.H.; Chen, H.; Shen, W.; Payne, R.M.; Liechty, E.A.; Caldwell, R.L.; Shou, W.; Field, L.J. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009, 119, 99–106.
    66. Zhao, Y.; McLaughlin, D.; Robinson, E.; Harvey, A.P.; Hookham, M.B.; Shah, A.M.; McDermott, B.J.; Grieve, D.J. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res. 2010, 70, 9287–9297.
    67. Li, J.Z.; Yu, S.Y.; Wu, J.H.; Shao, Q.R.; Dong, X.M. Paeoniflorin protects myocardial cell from doxorubicin-induced apoptosis through inhibition of NADPH oxidase. Can. J. Physiol. Pharmacol. 2012, 90, 1569–1575.
    68. Shimauchi, T.; Numaga-Tomita, T.; Ito, T.; Nishimura, A.; Matsukane, R.; Oda, S.; Hoka, S.; Ide, T.; Koitabashi, N.; Uchida, K.; et al. TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. JCI Insight 2017, 2.
    69. Sudi, S.B.; Tanaka, T.; Oda, S.; Nishiyama, K.; Nishimura, A.; Sunggip, C.; Mangmool, S.; Numaga-Tomita, T.; Nishida, M. TRPC3-Nox2 axis mediates nutritional deficiency-induced cardiomyocyte atrophy. Sci. Rep. 2019, 9, 9785.
    70. Faigle, M.; Seessle, J.; Zug, S.; El Kasmi, K.C.; Eltzschig, H.K. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS ONE 2008, 3, e2801.
    71. Paul, P.K.; Bhatnagar, S.; Mishra, V.; Srivastava, S.; Darnay, B.G.; Choi, Y.; Kumar, A. The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms. Mol. Cell. Biol. 2012, 32, 1248–1259.
    72. Dolmatova, E.; Spagnol, G.; Boassa, D.; Baum, J.R.; Keith, K.; Ambrosi, C.; Kontaridis, M.I.; Sorgen, P.L.; Sosinsky, G.E.; Duffy, H.S. Cardiomyocyte ATP release through pannexin 1 aids in early fibroblast activation. American journal of physiology. Heart Circ. Physiol. 2012, 303, H1208–H1218.
    1. Please check and comment entries here.